text: Piflufolastat F-18, sold under the brand name Pylarify among others, is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It is given by intravenous injection.
  The most common adverse reactions include headache, altered taste, and fatigue.
  Piflufolastat F-18 was approved for medical use in the United States in May 2021. It is the second PSMA-targeted PET imaging drug approved by the U.S. Food and Drug Administration (FDA). The first approved PSMA-targeted PET imaging drug is Ga 68 PSMA-11.